4 Readmission Predictors after Successful TAVR

4 Readmission Predictors after Successful TAVRReadmissions are frequent after cardiovascular procedures and they significantly increase healthcare costs. Data on readmission need within the first month after successful transcatheter aortic valve replacement (TAVR) are limited.

 

The registry included all TAVR patients surviving index hospitalization between January and February 2013 for readmission incidence, predictors, causes and costs within 30 days.

 

Of 12,221 included patients, 2,188 (17.9%) required readmission within 30 days.

 

Readmission predictors were:

  • length of stay longer than 5 days during index hospitalization
  • kidney injury (both acute and chronic)
  • transapical access
  • chronic lung disease

 

61.8% of these was due to non-cardiac causes and the remaining 38.2% was due to cardiac causes. Respiratory causes (14.7%), infections (12.8%), bleeding (7.6%) and peripheral vascular disease (4.3%) were the most common among non-cardiac causes, while heart failure (22.5%) and arrhythmia was the most common among cardiac causes (6.6%).

 

Readmissions median length was four more days.

 

Conclusion

Readmissions at 30 days after TAVR are frequent and are associated with comorbidities, access site and complications during index hospitalization. These predictors could alert about patients at high risk of readmission and prevent major complications.  

 

Original Title: Thirty-Day Readmissions after Transcatheter Aortic Valve Replacement in the United States. Insights from the Nationwide Readmissions Database.

Reference: Dhaval Kolte et al. Circ Cardiovasc Interv. 2017 Jan;10(1).


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Measuring Post-TAVI Gradients and Their Implications: Are Invasive and Echocardiographic Assessments Comparable?

Transcatheter aortic valve implantation (TAVI) is considered the treatment of choice for a significant proportion of patients with symptomatic aortic stenosis. Outcomes have improved...

Percutaneous Tricuspid Valve Replacement with Lux-Valve

Tricuspid regurgitation (TR) is a condition associated with poor quality of life, frequent hospitalizations due to heart failure, and increased mortality, even under optimal...

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Pretreatment with DAPT in Acute Coronary Syndrome: An Ongoing Debate?

In acute coronary syndrome (ACS) dual antiplatelet therapy (DAPT) has become a fundamental pillar after percutaneous coronary intervention (PCI), preventing stent thrombosis and acute...

Measuring Post-TAVI Gradients and Their Implications: Are Invasive and Echocardiographic Assessments Comparable?

Transcatheter aortic valve implantation (TAVI) is considered the treatment of choice for a significant proportion of patients with symptomatic aortic stenosis. Outcomes have improved...

Another Blow for Intra-Aortic Balloon Pumo Counterpulsation? Randomized Study on Its Use in Chronic Heart Failure Progressing to Cardiogenic Shock

Cardiogenic shock (CS) remains a condition with extremely high mortality (around 50%). While most therapies for this pathology have been studied in CS secondary...